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Abstract
Background: To evaluate the effect of lifestyle intervention in conjunction with rosiglitazone or placebo therapy
on left ventricular (LV) mass, using cardiovascular magnetic resonance (CMR) in the metabolic syndrome.
Methods: The present study was a pre-specified substudy of a double-blind randomized controlled trial evaluating
the effect of lifestyle intervention in conjunction with rosiglitazone or placebo therapy on carotid artery
atherosclerosis in the metabolic syndrome. From this original study population, 10 subjects from the placebo
group and 10 from the rosiglitazone group were randomly selected. At baseline and follow-up (52 weeks), clinical
and laboratory measurements were assessed and a CMR-examination was performed to evaluate LV mass indexed
for body surface area (LV mass-I). Subsequently, the effect of therapy (rosiglitazone vs. placebo) and clinical and
laboratory variables on LV mass-I was evaluated.
Results: In both groups, body mass index, waist circumference, systolic and diastolic blood pressure significantly
decreased during follow-up. Interestingly, LV mass-I significantly decreased in the placebo group (48.9 ± 5.3 g/m
2
vs. 44.3 ± 5.6 g/m
2, p < 0.001) indicating reverse remodeling, whereas LV mass-I remained unchanged in the
rosiglitazone group (54.7 ± 9.9 g/m
2 vs. 53.7 ± 9.2 g/m
2, p = 0.3). After correction for systolic and diastolic blood
pressure and triglyceride, the kind of therapy (rosiglitazone vs. placebo) remained the only significant predictor of
LV mass-I reduction.
Conclusions: Lifestyle intervention resulted in a reduction of LV mass-I in the metabolic syndrome, indicating
reverse remodeling. However, rosiglitazone therapy may have inhibited this positive reverse remodeling.
Trial registration: Current Controlled Trials ISRCTN54951661.
Background
The metabolic syndrome is a clustering of cardiovascu-
lar risk factors including abnormalities in glucose and
lipid metabolism, abdominal obesity and hypertension
[1], and is associated with increased risk of cardiovascu-
lar morbidity and mortality [2,3]. Although the exact
pathophysiologic mechanism underlying the metabolic
syndrome is still unclear, insulin resistance is believed to
play a central role in the development of the metabolic
syndrome [1,4]. Intensive lifestyle intervention by exer-
cise and weight loss has beneficial effects on cardiovas-
cular outcome in these patients. Also, pharmacological
agents have been developed to reduce insulin resistance
[5].
Peroxisome-proliferator-activated receptors (PPARs)
regulate gene expression in response to ligand binding
[5-7]. Thiazolidinediones (rosiglitazone, pioglitazone and
troglitazone) represent a group of insulin sensitizing
agents that can act as such ligands of the nuclear tran-
scription factor PPAR-g [5]. After ligand binding, PPARs
undergo specific conformational changes that allow for
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any medium, provided the original work is properly cited.the recruitment of coactivator proteins [8]. Ligands dif-
fer in their ability to interact with coactivators, which
explains the various biologic responses observed [6,7].
Clinical studies have shown that thiazolidinediones e.g.
lower blood glucose levels by enhancing hepatic and
peripheral glucose uptake and increase free fatty acid
uptake and storage in adipose tissue (thereby decreasing
free fatty acid uptake in other tissues) [5,9].
Previous studies revealed that patients with the meta-
bolic syndrome often present with increased left ventri-
cular (LV) mass (and LV hypertrophy) [10,11]. The
Framingham Heart Study evaluated LV mass using
echocardiography in relation to long-term clinical out-
come, and observed that an increase in LV mass is an
independent predictor of clinical events, including
death, attributable to cardiovascular disease [12].
The effect of thiazolidinediones on LV mass has been
studied previously in experimental and clinical settings,
but is however still unclear [13-17]. These clinical stu-
dies used 2-dimensional echocardiography to assess LV
function and LV mass [15,17]. Cardiovascular magnetic
resonance (CMR) however, is a highly reproducible
technique allowing for more accurate measurement of
LV mass, enabling reduction of sample size [18].
Accordingly, the purpose of the present study was to
evaluate the effect of lifestyle intervention in conjunc-
tion with rosiglitazone or placebo therapy on LV mass
using CMR in subjects with the metabolic syndrome.
Methods
The present study was a pre-specified substudy of a
double-blind randomized controlled trial evaluating the
effect of lifestyle in conjunction with rosiglitazone or
placebo therapy on carotid artery atherosclerosis in sub-
jects with the metabolic syndrome (Rosiglitazone versUs
placeBo on the prevENtion of progression of athero-
Sclerosis, RUBENS trial).
For this trial, 116 Caucasian male subjects with
increased waist circumference (≥ 94 cm) and elevated
CRP levels (≥ 1.8 mg/L), and two other metabolic syn-
drome criteria according to the International Diabetes
Federation criteria [19] were selected. Exclusion criteria
included type 2 diabetes (fasting blood glucose ≥ 7
mmol/l), manifest cardiovascular disease, use of statins,
steroids or non-steroidal anti-inflammatory drugs at
baseline, heart failure (New York Heart Association
class I or higher), QTc time interval of 450 ms or longer
on baseline electrocardiogram (ECG), primary dyslipide-
mias, presence of potential hepatic disease (i.e. subjects
with alanine aminotransferase, total bilirubin, or alkaline
phosphatase levels exceeding 2.5 times the upper limit
of the normal laboratory values), alcohol abuse (> 30
units/week) and CMR contraindications. The study con-
sisted of two periods: the screening phase and a double-
blind study period with a scheduled duration of 52
weeks. After the screening phase, eligible subjects were
randomly assigned in a 1:1 ratio (using computer gener-
ated codes) to receive either daily therapy with 8 mg of
rosiglitazone or placebo. The treatment was titrated:
during the first eight weeks, the participants were trea-
ted with one tablet daily (rosiglitazone 4 mg or placebo),
which was doubled after 8 weeks. Subsequently, all sub-
jects were submitted to intensive lifestyle changes
including a 1500 kCal diet. In addition, the participants
were motivated to increase their level of daily physical
activity aiming at an extra energy-expenditure of 270
kCal per day (i.e. a normal-pace walk of 30 minutes,
three times daily). All subjects were closely monitored
during the study by the study physician and vascular
nurse at 8, 22, 36 and 52 weeks after randomization/
baseline. Hypertension was treated using a predefined
protocol: first with salt restriction followed by step-up
pharmacological therapy if needed, starting with hydro-
chlorothiazide 12.5 mg followed by ACE inhibition.
From this original study population, 10 subjects from
the placebo group and 10 subjects from the Rosiglita-
zone group were randomly selected (sample size calcula-
tion by Bellenger et al. [18]: using CMR, 9 subjects are
needed to detect a 10 g change in LV mass with a
power of 90% and an a error of 0.05, corresponding
with a 4.5 g change in LV mass-I [average body surface
area 2.2]). These 20 subjects underwent a CMR exami-
nation at baseline to evaluate LV mass (primary end-
point), LV volumes and LV systolic function.
Assessment of clinical measurements (body mass index,
waist circumference, blood pressure) and laboratory
measurements (triglycerides, high-density lipoprotein
cholesterol [HDL cholesterol], total cholesterol, fasting
blood glucose, glycated hemoglobin, insulin, high-sensi-
tivity C-reactive protein [hs-CRP]) were performed just
prior to CMR. Insulin resistance was calculated accord-
ing to the homeostatic model assessment method
(HOMA-IR) [20]. CMR examination, and clinical and
laboratory measurements were repeated after one year.
Approval by the local ethics committee and informed
consent were obtained.
CMR data acquisition
CMR was performed on a 1.5T Gyroscan ACS-NT/
Intera MRI scanner (Philips Medical Systems, Best, The
Netherlands) equipped with powertrack 6000 gradients
and 5-element cardiac synergy coil.
For evaluation of LV mass, LV volumes and LV systo-
lic function, the heart was imaged in short-axis view
from apex to base, with 10-12 imaging levels (dependent
on heart size) using an ECG-triggered balanced turbo
field-echo sequence [21]. Typical parameters were a
f i e l do fv i e wo f4 0 0×4 0 0m m
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Page 2 of 8pixels, slice thickness of 10.00 mm, no slice gap, flip
angle of 50°, time to echo of 1.82 ms, and time to repeat
of 3.65 ms. Temporal resolution was 25 to 39 ms.
CMR data analysis
Data were analyzed with MASS software developed at
our institution (Medis, Leiden, the Netherlands). Analysis
was performed by the same researcher (initials S.D.R.)
with more than five years experience in CMR. To deter-
mine LV mass, LV systolic function and volumes, endo-
cardial and epicardial borders were manually traced on
t h es h o r t - a x i sc i n ei m a g e s .P a p i l l a r ym u s c l e sw e r e
regarded as part of the ventricular cavity. LV mass, LV
end-systolic volume (LV ESV), LV end-diastolic volume
(LV EDV) and ejection fraction (EF) were assessed. LV
mass, LV EDV and LV ESV were corrected for body sur-
face area (yielding LV mass-I, LV EDV-I and LV ESV-I).
Statistical analysis
Continuous variables were tested for normal distribution
(by evaluation of normal Q-Q plots of residuals obtained
after correction for between group effects) and
expressed as mean ± standard deviation (SD) or median
(interquartile range). Differences at baseline and at fol-
low-up between groups (rosiglitazone vs. placebo group)
were analyzed using the unpaired t-test, Mann-Whitney
U-test (numerical data) or Fisher’s exact test (categorical
data) as appropriate. Variables at baseline were com-
pared to follow-up using the paired t-test, Wilcoxon
singed rank test (numerical data) or McNemar’st e s t
(categorical data). Changes in variables from baseline to
follow-up between subjects who received rosiglitazone
and placebo therapy were compared using the unpaired
t-test or Mann-Whitney U-test. Non-normally distribu-
ted variables were log transformed for further analysis.
Furthermore, the relation between the kind of therapy
(rosiglitazone vs. placebo) and changes in LV mass-I
(primary endpoint), and alterations in clinical and CMR
variables between baseline and follow-up and changes in
LV mass-I (primary endpoint) were evaluated. (Pearson’s
correlation coefficients (r), p-values reported). Subse-
quently, variables with a significant relation or trend
towards a significant relation with LV mass-I (p < 0.10)
were included in a multiple linear regression model to
evaluate the relation between these variables and LV
mass-I. Furthermore, in order to correct for possible dif-
ferences in LV mass-I at baseline, we have included this
variable in the multiple linear regression model.
Results
Clinical and laboratory characteristics
At baseline, no differences in clinical and laboratory
variables were observed between subjects who were ran-
domized for rosiglitazone or placebo therapy. Variables
at baseline and follow-up for the subjects who received
rosiglitazone therapy and subjects who received placebo
therapy are presented in Table 1. For both groups, body
mass index, waist circumference, systolic and diastolic
blood pressure significantly decreased from baseline to
follow-up. In the placebo group, no significant change
was observed in laboratory variables, except for a
decrease in insulin (from 11.5 (9.3) to 7.0 (5.8), p =
0.007) and HOMA-IR (from 1.6 (1.1) to 0.9 (0.8), p =
0.007). In the rosiglitazone group, the level of triglycer-
ides, insulin, HOMA-IR and hs-CRP significantly
decreased, whereas HDL cholesterol significantly
increased.
CMR variables
Table 2 shows the CMR variables at baseline and follow-
up for subjects who received rosiglitazone or placebo
therapy in conjunction to lifestyle intervention, respec-
tively. Except for LVEDV-I (91 ± 12 vs. 78 ± 6 ml/m
2,p
= 0.007, resp. rosiglitazone and placebo), CMR variables
were similar between the two groups at baseline. LV
mass-I at baseline was not significantly different between
both groups (p = 0.13). In both groups, LV EDV en LV
ESV and LVEF did not significantly change between
baseline and follow-up. Interestingly, no significant
change in LV mass-I was observed in the rosiglitazone
group (54.7 ± 9.9 g/m
2 vs. 53.7 ± 9.2 g/m
2,p=0 . 3 ) ,
whereas LV mass-I significantly decreased in the subjects
who were treated with placebo therapy (48.9 ± 5.3 g/m
2
vs. 44.3 ± 5.6 g/m
2, p < 0.001). Accordingly, mean LV
mass-I decreased 1.0 ± 2.5 g/m
2 in the rosiglitazone
group vs. 4.6 ± 1.9 g/m
2 in the placebo group (p = 0.002).
None of the alterations in clinical and laboratory vari-
ables during follow-up correlated significantly with the
change in LV mass-I. Only a trend towards a significant
correlation was observed between change in triglyceride,
systolic and diastolic blood pressure between baseline
and follow-up and reduction in LV mass-I (r = -0.392, p
= 0.087, r = -0.392, p = 0.087 and r = -0.384, p = 0.095,
respectively).
The multiple linear regression models to assess the
relative effect of rosiglitazone therapy, systolic and dia-
stolic pressure and triglyceride on LV-mass-I are pre-
sented in Table 3. After correction for systolic and
diastolic blood pressure and triglyceride, the kind of
therapy (rosiglitazone vs. placebo) remained the only
significant predictor of the extent of LV mass-I reduc-
tion. Also, after correction for LV mass-I at baseline, the
kind of therapy remained the only significant predictor
of LV mass-I reduction.
Discussion
The main findings in the current study are as follows:
intensive lifestyle intervention including a diet and
Roes et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:65
http://www.jcmr-online.com/content/13/1/65
Page 3 of 8Table 1 Clinical and laboratory variables at baseline and follow-up
Clinical variables Rosiglitazone therapy Placebo therapy Rosiglitazone therapy Placebo therapy
Baseline Follow-up P-value Baseline Follow-up P-value Δ baseline-follow-up Δ baseline-follow-up P-value
Age (yrs) 60 ± 6 61 ± 6 < 0.001 57 ± 5 58 ± 5 < 0.001
Body mass index (kg/m
2) 30.3 ± 4.5 28.7 ± 4.8 0.001 31.4 ± 4.9 29.2 ± 3.8 0.022 -1.6 ± 1.0 -2.2 ± 2.5 0.5
Waist circumference (cm) 112 ± 11 104 ± 14 0.001 111 ± 12 102 ± 10 0.005 -8 ± 5 - 8 ± 7 0.9
Systolic blood pressure (mmHg) 154 ± 23 136 ± 15 0.021 149 ± 14 135 ± 11 0.001 -18 ± 21 -14 ± 9 0.6
Diastolic blood pressure (mmHg) 91 ± 11 78 ± 8 0.001 89 ± 6 78 ± 5 < 0.001 -13 ± 9 -11 ± 5 0.6
Antihypertensive drugs, N (%) 2 (20) 4 (40) 0.5 4 (40) 4 (40) 1.0
Laboratory variables
Triglycerides (mmol/l) 1.8 ± 0.5 1.4 ± 0.3 0.008 1.9 ± 0.7 1.7 ± 0.6 0.3 -0.4 ± 0.4 -0.2 ± 0.5 0.3
HDL cholesterol (mmol/l) 1.2 ± 0.2 1.4 ± 0.2 0.002 1.2 ± 0.2 1.2 ± 0.1† 0.7 0.2 ± 0.2 0.02 ± 0.2 0.024
LDL cholesterol (mmol/l) 3.8 ± 0.8 4.3 ± 0.6 0.079 3.9 ± 0.4 3.8 ± 0.5 0.7 0.6 ± 0.9 -0.06 ± 0.4 0.063
Total cholesterol (mmol/l) 5.8 ± 0.9 6.3 ± 0.7 0.1 5.9 ± 0.6 5.8 ± 0.6 0.5 0.6 ± 1.0 -0.1 ± 0.6 0.075
Fasting blood glucose (mmol/l) 5.0 ± 0.6 4.8 ± 0.7 0.098 5.7 ± 1.0 5.3 ± 1.1 0.071 -0.3 ± 0.5 -0.4 ± 0.6 0.6
HbA1c (%) 5.2 ± 0.6 5.3 ± 0.4 0.3 5.2 ± 0.4 5.3 ± 0.3 1.0 0.1 ± 0.3 0.0 ± 0.4 0.5
Insulin (mmol/l)* 11.5 (11.3) 6.0 (4.3) 0.034 11.5 (9.3) 7.0 (5.8) 0.007 -4.2 ± 5.0 -7.6 ± 7.3 0.3
HOMA-IR (mmol/l × mU/l)* 1.5 (1.5) 0.6 (0.5) 0.021 1.6 (1.1) 0.9 (0.8) 0.007 -0.6 ± 0.6 -1.1 ± 1.0 0.2
hs-CRP (mmol/l)* 2.4 (3.1) 1.6 (1.7) 0.047 2.6 (0.9) 2.6 (2.6) 0.6 -1.7 ± 2.5 7.0 ± 21.2 0.2
Data are expressed as mean ± SD. * Variables were non-normally distributed and therefore expressed as median (interquartile range); Mann-Whitney U test or Wilcoxon singed rank test were used for comparison
between groups and between baseline and follow-up, respectively.
† p < 0.05 between subjects who received Rosiglitazone or placebo therapy at follow-up.
HbA1c: glycated hemoglobin, HDL cholesterol: high-density lipoprotein cholesterol, HOMA-IR: homeostasis model assessment of insulin resistance (fasting blood glucose (mmol/l) × fasting insulin (mU/l)/22.5), hs-CRP:
high-sensitivity C-reactive protein, LDL cholesterol: low-density lipoprotein cholesterol.
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8physical exercise in conjunction with either rosiglitazone
or placebo therapy, improves clinical characteristics
such as body mass index, waist circumference, diastolic
and systolic blood pressure. Furthermore, lifestyle inter-
vention in conjunction with rosiglitazone or placebo
therapy results in a significant decrease in insulin and
insulin resistance (HOMA-IR). Also, in subjects who
were randomised for rosiglitazone therapy, a significant
increase in HDL cholesterol and a decrease in triglycer-
ide and hs-CRP was observed, whereas no change in
these variables was observed in subjects who used pla-
cebo therapy. Interestingly, lifestyle intervention in con-
junction with placebo therapy resulted in a reduction of
LV mass-I, whereas in subjects who were randomised
for rosiglitazone therapy, LV mass-I remained
unchanged.
Clinical variables
All subjects in our study were submitted to lifestyle
intervention including a diet and exercise, which
resulted in reduction of body mass index and waist
circumference. This lifestyle intervention also signifi-
cantly lowered systolic and diastolic blood pressure
regardless of therapy (rosiglitazone or placebo). It is well
k n o w nt h a tw e i g h tr e d u c t i o nl o w e r sb l o o dp r e s s u r e
[22-24]. Systemic reviews of studies evaluating the effect
of rosiglitazone have indeed not found any beneficial
effects of rosiglitazone on blood pressure, which is in
line with the results of the present study [5,25].
Laboratory measurements
In both groups, thus regardless of treatment, insulin
levels and insulin resistance significantly improved dur-
ing follow-up. A major contributor to the development
of insulin resistance (and thus higher levels of insulin) is
the overabundance of free fatty acids produced in adi-
pose tissue [1]. These free fatty acids lead to higher glu-
cose and insulin levels through different pathways. For
instance, free fatty acids stimulate production of glucose
by the liver and high levels of free fatty acids lead to
reduction of insulin sensitivity by inhibition of insulin-
mediated glucose uptake in peripheral tissues [1].
Table 3 Multivariable association clinical and laboratory variables and LV mass-I reduction
Β-coefficient P-value
a R
2 P-value
b
Model 1 0.421 0.002
Rosiglitazone therapy 3.6 (1.5-5.7) 0.002
Model 2 0.516 0.002
Rosiglitazone therapy 3.2 (1.1-5.3) 0.006
Δ systolic blood pressure -0.03 (-0.12-0.06) 0.5
Δ diastolic blood pressure -0.07 (-0.27-0.12) 0.4
Δ triglyceride -0.68 (-.2-1.8) 0.6
Model 3 0.611 0.01
Rosiglitazone therapy 3.7 (1.7-5.7) 0.003
Δ systolic blood pressure -0.01 (-0.09-0.08) 0.9
Δ diastolic blood pressure -0.11 (-0.29-0.07) 0.3
Δ triglyceride -1.0 (-3.3-1.3) 0.4
LV mass-I at baseline -0.1 (-0.2-0.3) 0.2
a Level of significance of the association between the separate components of the model and reduction in LV mass-I.
b Level of significance of the model.
LV mass-I: left ventricular mass indexed for body surface area
Table 2 CMR variables at baseline and follow-up
Rosiglitazone therapy Placebo therapy Rosiglitazone therapy Placebo therapy
Baseline Follow-up P-value Baseline Follow-up P-value Δ baseline-follow-up Δ baseline-follow-up P-value
CMR variables
LV EDV-I (ml/m
2) 91.1 ± 11.8 92.3 ± 5.1 0.7 78.7 ± 6.4 † 80.7 ± 10.7‡ 0.5 1.2 ± 10.4 1.9 ± 9.0 0.9
LV ESV-I (ml/m
2) 38.3 ± 8.9 36.8 ± 5.0 0.4 32.0 ± 4.5 32.5 ± 7.8 0.8 -1.5 ± 5.9 0.5 ± 6.2 0.5
LV mass-I (g/m
2) 54.7 ± 9.9 53.7 ± 9.2 0.3 48.9 ± 5.3 44.3 ± 5.6‡ < 0.001 -1.0 ± 2.5 -4.6 ± 1.9 0.002
LVEF (%) 58.1 ± 6.7 60.1 ± 4.9 0.095 59.3 ± 4.4 60.0 ± 5.7 0.6 2.0 ± 3.3 0.7 ± 3.9 0.4
† p < 0.05 between subjects who received rosiglitazone or placebo therapy at baseline.
‡ p < 0.05 between subjects who received rosiglitazone or placebo therapy at follow-up.
LV EDV-I: left ventricular end-diastolic volume indexed for body surface area, LV ESV-I: left ventricular end-systolic volume indexed for body surface area: LV
mass-I: left ventricular mass indexed for body surface area, left ventricular, LVEF: left ventricular ejection fraction.
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sue) will reduce insulin levels and insulin resistance.
Results from large clinical trials indeed showed that life-
style changes significantly reduced the incidence of dia-
betes [26,27]. Thiazolidinediones act as insulin
sentitizers by multiple mechanisms and a previous study
in non-diabetic insulin resistant individuals indeed
demonstrated lower insulin and improvement of insulin
resistance after rosiglitazone treatment [28]. In the cur-
rent study, no additional effect of rosiglitazone on insu-
lin and insulin resistance could be observed, stressing
the highly beneficial effects of lifestyle intervention,
overshadowing the possible effect of rosiglitazone on
these parameters.
The finding that rosiglitazone increases HDL choles-
terol is in accordance with previous clinical trials evalu-
ating the effect of rosiglitazone on lipid profile in
patients with type 2 diabetes, in which HDL cholesterol
levels increased approximately 10 percent [29-31]. These
studies also found an adverse effect on low-density lipo-
protein (LDL) cholesterol levels after rosiglitazone ther-
apy. Although no significant change could be observed
in our study, LDL cholesterol levels indeed increased in
patients using rosiglitazonet h e r a p y .I nt h eg r o u pu s i n g
rosiglitazone, a significant reduction in triglycerides was
noted. Previous studies revealed controversial results on
the effect of rosiglitazone on triglycerides; some studies
showed a similar decrease in triglycerides as was
observed in the current study, whereas others found no
effect on triglyceride level [30,32,33].
Left ventricular mass
Previous studies showed that subjects with the metabolic
syndrome often present with increased LV mass (and
LV hypertrophy) [10,11] The Framingham Heart Study
evaluated LV mass using echocardiography and observed
that increased LV mass is an independent predictor of
clinical events such as heart failure, ischemia, ventricular
arrhythmia, and sudden cardiac death [12]. Accordingly,
reduction of LV mass is important for improvement of
clinical outcome. Several studies reported that weight
loss is associated with a reduction in LV mass [34-36].
Ar e c e n ts t u d yb yR i d e re ta l .[ 3 5 ]e v a l u a t e do b e s e
patients who underwent bariatric surgery, and found a
regression of LV hypertrophy in these patients. The
results from the current study show LV mass-I signifi-
cantly decreased in subjects who underwent extensive
lifestyle intervention (resulting in weight reduction) in
conjunction with placebo therapy. Accordingly, intensive
lifestyle intervention including a diet and exercise results
in reverse remodeling of the LV in subjects with the
metabolic syndrome. However, the use of rosiglitazone
may have inhibited this beneficial effect of lifestyle
intervention, as LV mass-I remained unchanged in this
group.
The effect of rosiglitazone therapy on LV mass has
been studied in experimental and clinical setting, how-
ever revealing controversial results [13-17]. Evidence
from experimental studies has shown that administra-
tion of thiazolidinediones might be associated with the
development of LV hypertrophy [14,37,38]. Bell et al.
[14] investigated the trophic effects of rosiglitazone on
cardiomyocytes in an experimental in-vitro model and
observed that rosiglitazone itself does not iniate cellular
hypertrophy directly. However, their results might sug-
gest that rosiglitazone in combination with growth-regu-
lating factors may make a modest contribution to
cardiac remodeling (hypertrophy). Duan et al. [38] stu-
died the effect of rosiglitazone in cardiomyocyte-specific
PPAR-g knock-out mouse model and in control mice
and observed that rosiglitazone causes cardiac hypertro-
phy in both models, however more pronounced in the
control mice, suggesting also a partially PPAR-g inde-
pendent mechanism responsible for the hypertrophic
effects. On the other hand, studies have reported that
thiazolidinediones inhibit cardiac hypertrophy [13,16].
Asakawa et al. [13] evaluated the effect of thiazolidine-
diones in-vitro on cultured rat cardiac myocytes and in-
vivo using mice (exposed to angiotensine II or pressure
overload to induce hypertrophic remodeling) and
observed that thiazolidinedione therapy inhibit cardiac
hypertrophy.
Thus far, only few studies have evaluated the possible
hypertrophic effect of thiazolidinediones in patients
[15,17]. St. John Sutton et al. [17] studied patients with
type 2 diabetes using echocardiography and demon-
strated that long-term use of rosiglitazone is not asso-
ciated with increase in LV mass (or functional
impairment). Likewise, Ghazzi et al. [15] performed an
echocardiographic study in patients with type 2 diabetes
submitted to troglitazone therapy and could not observe
an increase in LV mass either.
Accordingly, the current study is the first study that
evaluated the effect of rosiglitazone therapy on LV
mass-I in subjects with the metabolic syndrome using
CMR and revealed that rosiglitazone inhibits the positive
effects (of reverse remodeling) of intensive lifestyle inter-
vention. Due to the observational character of this study,
the underlying mechanism remains to be elucidated.
Possible explanations maybe that the effect of rosiglita-
zone on cardiomyocytes might inhibit the process of
reverse remodeling directly. Or, the concurrent hyper-
trophic effect of rosiglitazone may minimize the effect
of reverse remodeling (reduction of LV mass) due to
lifestyle intervention, resulting in unchanged LV mass.
Besides a direct effect of rosiglitazone on
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affect hemodynamics by increasing mechanical loading
through different mechanisms: thiazolidinediones may
increase cardiac output due to decreased afterload as a
consequence of decreased peripheral resistance, and
enhanced fluid retention leading to increased cardiac
preload [5,14]. The effect of reverse remodeling (LV
mass reduction) due to lifestyle intervention and the
simultaneously occurring haemodynamic effects of rosi-
glitazone might cancel each other out.
In two patients from the group following rosiglitazone
therapy, anti-hypertensive medication was initiated dur-
ing the course of the study. Two other patients from
this group were already treated with anti-hypertensive
medication at baseline, as well as four patients from the
p l a c e b og r o u p .T h ef a c tt h a tmedication was initiated
during the study in patients from the rosiglitazone
group, would potentially imply additional LV mass
reduction in this group. And since LV mass-I was not
significantly different for these patients at follow-up, this
observation may even add to the possible cancelling
effect of rosiglitazone on reverse LV remodeling.
The fact that the previous clinical studies [15,17] were
not able to find an effect of thiazolidinedione on LV
mass might be explained by the use of CMR, enabling
highly accurate measurements of LV mass [18] in stead
of echocardiography which is operator and acoustic win-
dow dependent [39].
During the past few years, the safety of rosiglitazone
therapy has been a matter of debate. Nissen and Wolski
[40] performed a meta-analysis to study the effect of
rosiglitazone on cardiovascular morbidity and mortality
and concluded that rosiglitazone therapy was associated
with an increased risk of myocardial infarction. The
recently published RECORD trial evaluated the effect of
addition of rosiglitazone to glucose-lowering therapy
and found an increased risk of heart failure in patients
treated with rosiglitazone compared to controls, whereas
the overall cardiovascular morbidity and mortality was
similar [41]. The results of the current study, suggesting
a hypertrophic effect of rosiglitazone, and the previously
recognized relation between LV hypertrophy and cardiac
events such as ischemia and heart failure [12], might
add to the paradigm of sodium and water retention to
explain the increased risk of these events in patients
using rosiglitazone.
A limitation of the present study is the relatively small
study population. However, the use of CMR allows for
very accurate and reproducible measurements enabling
significant reduction in sample size [18].
Conclusion
Intensive lifestyle intervention resulted in LV mass-I
reduction in subjects with the metabolic syndrome,
indicating reverse remodeling. However, rosiglitazone
therapy may have inhibited this positive reverse remo-
deling (LV mass-I reduction).
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